Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JNJ and other ETFs, options, and stocks.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
131,900
Employees131,900
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
131,900
Employees131,900

JNJ Key Statistics

Market cap
372.24B
Market cap372.24B
Price-Earnings ratio
22.27
Price-Earnings ratio22.27
Dividend yield
3.08%
Dividend yield3.08%
Average volume
6.59M
Average volume6.59M
High today
$155.00
High today$155.00
Low today
$153.71
Low today$153.71
Open price
$154.81
Open price$154.81
Volume
6.51M
Volume6.51M
52 Week high
$175.97
52 Week high$175.97
52 Week low
$143.13
52 Week low$143.13

JNJ News

Seeking Alpha 4h
Novo Nordisk, J&J lead R&D rankings in big pharma: report

Weight loss drugmaker Novo Nordisk (NVO) and U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) have become the most transformative companies in big pharma, acc...

Novo Nordisk, J&J lead R&D rankings in big pharma: report
Seeking Alpha 10h
Johnson & Johnson-backed Rapport Therapeutics files for $100M IPO

Rapport Therapeutics, a clinical-stage biopharma backed by the venture capital arm of Johnson & Johnson (NYSE:JNJ), submitted SEC filings on Friday to raise up...

Johnson & Johnson-backed Rapport Therapeutics files for $100M IPO
Simply Wall St 1d
Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution

The fact that multiple Johnson & Johnson (NYSE:JNJ) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongs...

Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution

Analyst ratings

52%

of 23 ratings
Buy
47.8%
Hold
52.2%
Sell
0%

More JNJ News

Reuters 1d
J&J-backed startup Rapport files for US IPO

(Reuters) -Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson, filed for an initial public offering in the U...

J&J-backed startup Rapport files for US IPO
Financial Times 2d
‘Reverse Yankee’ deals boom as Europe’s low borrowing costs lure US groups

Print this page US companies are flocking to Europe’s bond markets as an uptick in cross-border mergers and acquisitions and a rethink on the path of interest...

‘Reverse Yankee’ deals boom as Europe’s low borrowing costs lure US groups
Yahoo Finance 2d
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M - Yahoo Finance

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix...

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M - Yahoo Finance
Yahoo Finance 2d
Johnson & Johnson Up 5.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance

A month has gone by since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 5.5% in that time frame, underperforming the S&P 500. W...

Johnson & Johnson Up 5.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Seeking Alpha 2d
Johnson & Johnson to buy dermatology-focused biotech Proteologix

Johnson & Johnson (NYSE:JNJ) announced Thursday an agreement to acquire Proteologix, a privately held biotech focused on developing drugs for the immune-mediate...

Johnson & Johnson to buy dermatology-focused biotech Proteologix
Reuters 2d
UPDATE 1-Johnson & Johnson to acquire Proteologix for $850 million

(Adds details on Proteologix's drug in paragraph 2, and J&J drug in paragraph 4) May 16 (Reuters) - Johnson & Johnson said on Thursday it would acquire Proteol...

UPDATE 1-Johnson & Johnson to acquire Proteologix for $850 million
Yahoo Finance 2d
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment - Yahoo Finance

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD) Includes bi...

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.